Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05473143

Proactive Prescription-based Fluid Management vs Usual Care in Critically Ill Patients on Kidney Replacement Therapy

A pilot randomized clinical trial comparing a protocol-based fluid management strategy to usual care in critically ill patients receiving kidney replacement therapy. The fluid management protocol is intended to achieve neutral or negative daily fluid balance by both preventing and treating fluid accumulation.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre Hospitalier de l'Université de Montréal

Montreal, Quebec, H2X0A9, Canada

About this study

Severe acute kidney injury (AKI) in the intensive care unit (ICU) is almost uniformly complicated by fluid accumulation, thus making fluid removal a central component of the renal replacement therapy (KRT) prescription. Whereas the achievement and maintenance of euvolemia are critical objectives in the care of critically ill patients with severe AKI, there remain important knowledge gaps in our ability to effectively and safely deliver ultrafiltration. Multisystemic congestion resulting from fluid accumulation is believed to mediate adverse outcomes in this population and the timely use of mechanical fluid removal may improve prognosis. However, fluid removal may be associated with hemodynamic instability during KRT which may precipitate complications. The optimal fluid management strategy is currently unknown.

The study is a pilot randomized clinical trial comparing a protocol-based fluid management strategy with usual care in critically ill patients receiving KRT. The fluid management protocol is intended to achieve neutral or negative daily fluid balance by both preventing and treating fluid accumulation. The protocol was designed to provide a standardized framework to prescribe fluid removal while allowing the attending care team to modify treatment targets according to their clinical evaluation.

The primary objective of this trial is to determine whether the intervention results in a difference in cumulative fluid balance from randomization to 5 days. Feasibility will be documented including the ability to enroll the target population, protocol adherence, and the capacity to achieve follow-up through 90 days. Secondary outcomes will also include short-term patient outcomes, safety outcomes, and health resource utilization related to KRT delivery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Admitted to the ICU
  • AKI during current hospitalization defined by the Kidney Disease: Improving Global Outcomes (KDIGO) criteria(1) as any of the following: Increase in serum creatinine by 27 µmol/L or more within any 48-hour window, or an increase in serum creatinine to 1.5 times baseline or more within the last 7 days, or a urine output less than 0.5 mL/kg/h for 6 hours.
  • Planned initiation of KRT within the following 12 hours or the receipt of KRT for AKI for ≤48 hours

Exclusion criteria

  • Lack of commitment to maintain kidney, pharmacologic or respiratory support at the time of screening, or probable transition to comfort care within 48 hours according to the treating physician
  • Probable discharge from the ICU within the next 48 hours according to treating physician
  • Severe burn injury (>10% of body surface area)
  • Severe abnormality in serum sodium (>155 or <120 mmol/L)
  • Important ongoing fluid losses are present and/or are expected to require continued maintenance IV fluids uring the next 48 hours
  • The clinical care team believes that the proposed intervention is inappropriate.

Treatment and study plan

Protocol-based fluid management

Other

Fluid removal will be prescribed using a standardized template updated at least once per working day, before noon of each day, by the attending care team. This protocolized prescription will contain three components. Fluid removal will be prescribed using a standardized template updated at least once per working day, before noon of each day, by the attending care team. This protocolized prescription will contain three components.

The first component of this prescription will be to define the 24h-fluid balance target either aiming for a negative fluid balance of 2 to 3% body weight (1.4-2.1 liters in a 70 Kg participant) (Option 1) or by aiming to avoid fluid accumulation by targeting a neutral fluid balance within 0.5% of body weight variation (-350 to +350 mL in a 70 Kg participant) (Option 2).

The second component is to pre-specify a prescription for fluid removal using KRT.

The third component is to prompt a daily re-evaluation of fluid intake by the attending care team.

Usual Care

Other

The net fluid removal and the rate of net fluid removal will not be protocolized and will be prescribed and adjusted according to the attending care team without any specific guidance. The use of the documents provided for the intervention group will not be permitted in the control arm.

Primary outcomes

  1. Cumulative fluid balance

    Time frame: From randomization to the end of day 5

    The difference between quantifiable fluid intake and output

Secondary outcomes

  1. Feasibility: Ability to successfully enroll

    Time frame: During screening and enrolment

    Target >30% of fully eligible patients

  2. Feasibility: Protocol adherence

    Time frame: From randomization to the end of day 5

    defined as >80% of participants adhering to the allocated treatment for 5 days after enrolment

  3. Feasibility: Ability to achieve follow-up

    Time frame: From randomization through day 90.

    Ability to achieve > 95% follow-up regarding all clinical outcomes

  4. Clinical: Death

    Time frame: From randomization through day 90.

    Death from any cause

  5. Clinical: Vasoactive therapy-free days

    Time frame: From randomization through day 28.

    A vasoactive-free day will be defined as ≥ 2 hours of receipt of any vasoactive therapy provided by continuous infusion within a 24 hour period. Vasoactive therapy include norepinephrine, vasopressin, phenylephrine, epinephrine, dopamine >5mcg/kg/min, and angiotensin II.

  6. Clinical: Mechanical ventilation-free days

    Time frame: From randomization through day 28.

    A ventilator-free day will be defined as the receipt of ≥ 2 hours of mechanical ventilation within a 24-hour period.

  7. Clinical: KRT-free days

    Time frame: From randomization through day 28.

    An KRT-free day will be defined receiving any KRT modality for ≥ 2 hours within a 24 hours period.

  8. Clinical: ICU-free days

    Time frame: From randomization through day 90

    An ICU-free day will be defined as admission to an ICU for ≥ 2 hours within a 24 hours period.

  9. Clinical: Hospital-free days

    Time frame: From randomization through day 90

    Hospital-free days will be defined as a 24-hour period completely free of an inpatient hospitalization.

  10. Dependence on KRT

    Time frame: within +/- 7 days of the 90-day time point following randomization.

    KRT dependence will be defined by the receipt of any form of KRT

  11. Resource use: cumulative time of continuous KRT

    Time frame: From randomization to the end of day 5

    Total cumulative duration in hours

  12. Resource use: cumulative time of intermittent KRT

    Time frame: From randomization to the end of day 5

    Total cumulative duration in hours

  13. Safety: Maximal vasopressor requirements

    Time frame: From randomization to the end of day 5

    Maximal vasopressor requirements as per the vasoactive-inotropic score recorded during each 24-hour period.

  14. Safety: Severity of illness

    Time frame: From randomization to the end of day 5

    Total sequential organ failure assessment (SOFA) score recorded during each 24-hour period.

  15. Process measures: Target fluid balance as prescribed in the initial fluid balance prescription for the day

    Time frame: From randomization to the end of day 5

  16. Process measures: Proportion of time in which a neutral fluid balance target is selected by the clinical care team

    Time frame: From randomization to the end of day 5

  17. Process measures: Clinical elements used to assess fluid accumulation

    Time frame: From randomization to the end of day 5

  18. Process measures: The difference between the original target and the fluid balance achieved at the end of each 24-hour period

    Time frame: From randomization to the end of day 5

Sponsors and collaborators

Lead sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Other

Registry information

Acronym: Probe-Fluid

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Jul 25, 2022
Registry last updated
Mar 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.